HLA-G and cancer: Moreover, blockade of HLA-G with specific antibodies and the development of anti-HLA-G chimeric antigen receptor (CAR) NK or CAR-T cells have demonstrated that HLA-G is a valid target for cancer immunotherapy (17–21).